Chris Howerton
Stock Analyst at Jefferies
(2.62)
# 2,263
Out of 5,044 analysts
70
Total ratings
45.45%
Success rate
17.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.11 | +56.56% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $28.95 | +172.88% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.83 | +118.58% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $3.65 | +173.97% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.18 | +16,046.79% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $18.38 | +3,817.30% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.71 | -70.76% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $20.18 | -50.45% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $18.59 | -40.83% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $30.05 | +33.11% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $29.64 | +105.80% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $133.51 | -32.59% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $5.58 | +115.05% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.90 | +2,119.76% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $27.06 | +143.90% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.60 | +292.86% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.13 | +885.92% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.62 | +1,258.02% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.61 | +1,333.02% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.62 | -7.16% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $17.16 | +3,279.95% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.25 | +4,700.00% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $71.56 | -77.64% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $78.51 | -65.61% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $5.94 | +20,102.02% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.11
Upside: +56.56%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $28.95
Upside: +172.88%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.83
Upside: +118.58%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $3.65
Upside: +173.97%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.18
Upside: +16,046.79%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $18.38
Upside: +3,817.30%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.71
Upside: -70.76%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $20.18
Upside: -50.45%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $18.59
Upside: -40.83%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $30.05
Upside: +33.11%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $29.64
Upside: +105.80%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $133.51
Upside: -32.59%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $5.58
Upside: +115.05%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.90
Upside: +2,119.76%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $27.06
Upside: +143.90%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.60
Upside: +292.86%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $2.13
Upside: +885.92%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.62
Upside: +1,258.02%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.61
Upside: +1,333.02%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.62
Upside: -7.16%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $17.16
Upside: +3,279.95%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.25
Upside: +4,700.00%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $71.56
Upside: -77.64%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $78.51
Upside: -65.61%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $5.94
Upside: +20,102.02%